Merck falls short in PhIII Covid-19 prophylaxis trial, joining Pfizer
Merck took another swing at bat to bolster its case for its Covid-19 antiviral — and that swing turned into yet another miss.
The pharma giant …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
